The landmark PANTHEON trial, a 1-year multicenter RCT in 1,006 Chinese COPD patients, found that high-dose NAC (600 mg twice daily) reduced the rate of acute exacerbations by 22% compared to placebo (1.16 vs 1.49 exacerbations per year, p=0.0011) (Zheng et al., Lancet Respir Med, 2014) [44]
Elucidation of the molecular mechanisms underlying sorafenib-induced hepatotoxicity
While NAC is generally considered safe and well-tolerated, some individuals should avoid it, including: People with asthma (NAC may trigger bronchospasm)
We therefore used female animals in our study
Missing one or two days in a cycle will not significantly affect outcomes
Glutone 1000 provides a efficient solution to increase glutathione levels and enhance the health of your skin